Brokerages Set Sotera Health (NASDAQ:SHC) Price Target at $16.08

Sotera Health (NASDAQ:SHCGet Free Report) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $16.08.

Several brokerages have recently issued reports on SHC. The Goldman Sachs Group initiated coverage on shares of Sotera Health in a research note on Friday, December 6th. They issued a “neutral” rating and a $14.00 price objective on the stock. Citigroup upped their price target on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Royal Bank of Canada reissued an “outperform” rating and set a $17.00 price objective on shares of Sotera Health in a research note on Thursday, November 21st. Finally, Barclays decreased their target price on Sotera Health from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th.

Read Our Latest Stock Report on SHC

Institutional Investors Weigh In On Sotera Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Darsana Capital Partners LP grew its stake in shares of Sotera Health by 716.9% in the 3rd quarter. Darsana Capital Partners LP now owns 20,010,000 shares of the company’s stock valued at $334,167,000 after buying an additional 17,560,636 shares in the last quarter. Vanguard Group Inc. lifted its stake in Sotera Health by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 14,923,546 shares of the company’s stock valued at $204,154,000 after acquiring an additional 173,341 shares during the last quarter. Sessa Capital IM L.P. grew its position in Sotera Health by 46.5% in the third quarter. Sessa Capital IM L.P. now owns 6,300,597 shares of the company’s stock worth $105,220,000 after acquiring an additional 2,000,000 shares in the last quarter. Sculptor Capital LP acquired a new position in shares of Sotera Health during the 4th quarter worth $68,400,000. Finally, State Street Corp raised its holdings in shares of Sotera Health by 18.5% during the 3rd quarter. State Street Corp now owns 4,126,806 shares of the company’s stock valued at $68,918,000 after purchasing an additional 644,236 shares in the last quarter. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Sotera Health Trading Down 0.7 %

Shares of SHC stock opened at $13.64 on Friday. The stock has a 50-day simple moving average of $13.48 and a 200 day simple moving average of $14.54. The stock has a market capitalization of $3.86 billion, a P/E ratio of 54.56 and a beta of 1.91. Sotera Health has a fifty-two week low of $10.71 and a fifty-two week high of $17.44. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91.

About Sotera Health

(Get Free Report

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.

Featured Stories

Analyst Recommendations for Sotera Health (NASDAQ:SHC)

Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.